Monday, July 12, 2010

While You Were Losing Ugly

What did we learn from the World Cup Final? Drop kicking is the new headbutting. Congratulations to the Spaniards, deserved winners last night.

Meanwhile, while you were getting ready for Avandia Week (sorry, Qnexa) ...
  • Merck-Serono's oral cladribine has been approved in Russia, and will be marketed there under the name Movectro beginning some time in 2011, once reimbursement is secured.

  • Biogen Idec and Swedish Orphan Biovitrum presented Phase I/II data on their long-acting Factor IX hemophilia B treatment at a conference in Argentina over the weekend.

  • Does Avid have an Alzheimer's biomarker on its hands with the radioactive dye AV-45? Reuters reports.

  • J&J is being sued over its children's OTC medicines recall, with plaintiffs seeking class action status. Apparently, they don't like coupons, reports Bloomberg.

  • Reata has raised $78 million in a Series G (as in goodness that's a lot of money) financing led by existing investors CPMG and Novo AS. The cash will fund a second pivotal trial of the company's lead asset, bardoxolone in chronic kidney disease.
screen cap by flickr user keith williamson used under a creative commons license

No comments: